Abstract

Hepatitis E virus (HEV) genotypes 3 and 4 (HEV-3, HEV-4) infections are an emerging public health issue in industrialized countries. HEV-3 and −4 are usually self-limiting but can progress to chronic hepatitis E in immunocompromised individuals. The molecular mechanisms involved in persistent infections are poorly understood. Micro RNAs (miRNAs) can regulate viral pathogenesis and can serve as novel disease biomarkers. We aimed to explore the modulation of serum miRNAs in patients with acute (AHE) and chronic (CHE) hepatitis E. Both AHE- and CHE-patients exhibited high viral loads (median 3.23E + 05 IU/mL and 2.11E + 06 IU/mL, respectively) with HEV-3c being the predominant HEV-genotype. Expression analysis of liver-specific serum miRNAs was performed using real-time PCR. miR-99a-5p, miR-122-5p, and miR-125b-5p were upregulated in AHE (4.70–5.28 fold) and CHE patients (2.28–6.34 fold), compared to HEV-negative controls. Notably, miR-192-5p was increased 2.57 fold while miR-125b-5p was decreased 0.35 fold in CHE but not in AHE patients. Furthermore, decreased miR-122-5p expression significantly correlates with reduced liver transaminases in CHE patients. To our knowledge, this marks the first investigation concerning the regulation of circulating liver-specific miRNAs in acute and chronic HEV infections. We found that miR-125b-5p, miR-192-5p, and miR-99a-5p may prove useful in the diagnosis of chronic hepatitis E.

Details

Title
Specific circulating microRNAs during hepatitis E infection can serve as indicator for chronic hepatitis E
Author
Harms Dominik 1 ; Choi, Mira 2 ; Allers Kristina 3 ; Wang, Bo 1 ; Pietsch Heiko 4 ; C-Patrick, Papp 1 ; Hanisch Lina 1 ; Kurreck Jens 5   VIAFID ORCID Logo  ; Hofmann, Jörg 6 ; C-Thomas, Bock 7   VIAFID ORCID Logo 

 Division of Viral Gastroenteritis and Hepatitis Pathogens and Enteroviruses, Department of Infectious Diseases, Robert Koch Institute, Berlin, Germany (GRID:grid.13652.33) (ISNI:0000 0001 0940 3744) 
 Medical Department, Division of Nephrology and Internal Intensive Care Medicine, Charité Universitätsmedizin Berlin, Berlin, Germany (GRID:grid.6363.0) (ISNI:0000 0001 2218 4662) 
 Medical Department, Division of Gastroenterology, Infectiology and Rheumatology (including Nutritional Medicine), Charité Universitätsmedizin Berlin, Berlin, Germany (GRID:grid.6363.0) (ISNI:0000 0001 2218 4662) 
 Department of Cardiology, Campus Rudolf Virchow, Charité Universitätsmedizin Berlin, Berlin, Germany (GRID:grid.6363.0) (ISNI:0000 0001 2218 4662); DZHK (German Centre for Cardiovascular Research), Berlin, Germany (GRID:grid.452396.f) (ISNI:0000 0004 5937 5237) 
 Institute of Biotechnology, Technical University of Berlin, Berlin, Germany (GRID:grid.6734.6) (ISNI:0000 0001 2292 8254) 
 Institute of Medical Virology, Charité Universitätsmedizin Berlin, Berlin, Germany (GRID:grid.6363.0) (ISNI:0000 0001 2218 4662); Labor Berlin, Charité-Vivantes GmbH, Berlin, Germany (GRID:grid.6363.0) 
 Division of Viral Gastroenteritis and Hepatitis Pathogens and Enteroviruses, Department of Infectious Diseases, Robert Koch Institute, Berlin, Germany (GRID:grid.13652.33) (ISNI:0000 0001 0940 3744); Institute of Tropical Medicine, University of Tübingen, Tübingen, Germany (GRID:grid.10392.39) (ISNI:0000 0001 2190 1447) 
Publication year
2020
Publication date
2020
Publisher
Nature Publishing Group
e-ISSN
20452322
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2382601282
Copyright
This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.